Key result
Elevated hsCRP was associated with increased all-cause death and MACCE in elderly patients with 3-vessel disease.
Why the study?
The prognostic value of high-sensitivity C-reactive protein (hsCRP) in complex coronary artery disease had not been fully established.
Does elevated hsCRP predict long-term outcomes in elderly patients with 3-vessel disease?
Cohort (n=3,069)
Does elevated hsCRP predict long-term outcomes in elderly patients with 3-vessel disease?
Answers are grounded in this paper and cite their sources.
Elevated hsCRP (≥3.00 mg/L) is an independent predictor of long-term mortality and MACCE in elderly patients with 3-vessel disease, and improves risk prediction when combined with the SYNTAX II score.
The prognostic value of high-sensitivity C-reactive protein (hsCRP) in complex coronary artery disease has not been fully established. We aimed to determine the association between hsCRP and long-term outcomes in elderly patients with 3-vessel disease (TVD). From April 2004 to February 2011, 3069 patients aged ≥65 years with TVD were consecutively enrolled and received medical treatment alone, percutaneous coronary intervention, or coronary artery bypass grafting. The patients were divided into 2 groups according to their hsCRP levels: <3.00 mg/L (62.1%) and ≥3.00 mg/L (37.9%). The mean age was 71 ± 4 years. The high hsCRP group had more risk factors and more frequently received conservative treatment than the low hsCRP group. During a median follow-up period of 6.2 years, elevated hsCRP was significantly associated with increased all-cause death (19.5% vs 29.6%, P < .001), cardiac death (9.4% vs 15.2%, P = .001), and major adverse cardiovascular and cerebrovascular events (34.1% vs 42.5%, P = .001). Multivariable Cox regression analyses revealed that hsCRP was an independent predictor for all of these events. Combining hsCRP with Synergy between PCI with TAXUS and Cardiac Surgery score II further improved the predictive power of the score. The relationship between hsCRP and mortality was relatively consistent across subgroups. Overall, hsCRP could prove useful for risk prediction in elderly patients.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2021) conducted a cohort in 3-vessel disease (n=3,069). Elevated high-sensitivity C-reactive protein (hsCRP ≥3.00 mg/L) vs. Low hsCRP (<3.00 mg/L) was evaluated on all-cause death (p=<.001). Elevated hsCRP was associated with increased all-cause death and MACCE in elderly patients with 3-vessel disease.
Synapse has enriched 10 related papers. Consider them for comparative context: